News

Ivax Diagnostics has posted a net loss of $0.96m for the first quarter 2010, or $0.03 per diluted share, compared $0.46m, or $0.02 per diluted share, for the

BioSante Pharma said that by incorporating 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines. The subsequent cell

Amgen’s Denosumab is a fully human monoclonal antibody in late stage clinical development that specifically targets Rank Ligand, the essential regulator of osteoclasts (the cells that break down

As per the terms of the agreement, Merck is expected to pay ElexoPharm an upfront payment of EUR1.5m. In addition ElexoPharm will be eligible to receive up to

Merck and Cardiome Pharma have presented the results of the Brinavess study during a late-breaking clinical trials session at Heart Rhythm 2010, the annual meeting of the Heart

Sodium lauryl sulfate (SLS) is a frequently used tabletting aid that works as a wetting agent, lubricant or solubilizer. GRAS status is recognition that Texapon K 12 P

Biostar Pharma has posted a net income of $2.26m for the first quarter 2010, or $0.08 per diluted share, compared to $1.82m, or $0.08 per diluted share, for

Boston Scientific said that leads are insulated wires that carry heart signals to the implanted device and deliver energy from the device to the heart. Leads are inserted

Beximco Pharma has posted a net profit of $.21m for the first quarter 2010, or $1.3 earnings per share (EPS), compared to $.12m, or $0.82 EPS, for the